Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)

Vertex Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$538.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 20.81% year-over-year to -$538.8 million; the TTM figure through Mar 2026 stood at -$2.1 billion (down 16.61% YoY), while the FY2025 annual figure was -$2.3 billion, down 51.27% from the prior year.
• Cash from Financing Activities was -$538.8 million for Q1 2026 at Vertex Pharmaceuticals, down from -$77.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $47.7 million in Q2 2022 to a low of -$1.2 billion in Q3 2025.
• Historically, Cash from Financing Activities has averaged -$289.7 million across 5 years, with a median of -$294.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 111.96% in 2022, then sank 2172.83% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $40.2 million in 2022, then sank by 398.01% to -$119.8 million in 2023, then plunged by 226.63% to -$391.3 million in 2024, then jumped by 80.27% to -$77.2 million in 2025, then tumbled by 597.93% to -$538.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$538.8 million (Q1 2026), -$77.2 million (Q4 2025), and -$1.2 billion (Q3 2025), per Business Quant data.